iSpecimen delays completion of 2025 annual meeting

iSpecimen Inc. is continuing efforts to complete its 2025 Annual Meeting of Stockholders.

Rhea-AI Filing Summary

iSpecimen Inc. is continuing efforts to complete its 2025 Annual Meeting of Stockholders. The meeting was first convened on December 31, 2025, but was repeatedly adjourned on January 23, 2026, February 13, 2026, March 13, 2026 and April 10, 2026 because a quorum was not present. The company now plans to reconvene the Annual Meeting on May 8, 2026 at 9:00 a.m. Eastern Time. The record date for stockholders entitled to vote remains November 3, 2025, and the proposals to be voted on are unchanged from those described in the definitive proxy statement filed on November 21, 2025.

Insights

Corporate governance analyst

Repeated quorum failures show shareholder participation challenges but no proposal changes.

iSpecimen has tried multiple times to hold its 2025 Annual Meeting, adjourning four reconvened sessions because a quorum was not present. This suggests many shareholders have not voted or attended despite ongoing solicitation based on the existing proxy.

The company will try again on May 8, 2026, keeping the November 3, 2025 record date and original proposals described in the November 21, 2025 proxy statement. The situation is administrative but highlights how low retail engagement can delay routine corporate business until sufficient votes are collected.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Initial 2025 Annual Meeting date: December 31, 2025 Reconvened meeting dates: Jan 23, Feb 13, Mar 13, Apr 10, 2026 Next reconvened meeting date: May 8, 2026 +2 more

5 metrics

Initial 2025 Annual Meeting date December 31, 2025 Original convening of 2025 Annual Meeting of Stockholders

Reconvened meeting dates Jan 23, Feb 13, Mar 13, Apr 10, 2026 Dates when meetings were reconvened without quorum

Next reconvened meeting date May 8, 2026 Planned reconvening of 2025 Annual Meeting at 9:00 a.m. Eastern

Record date for voting November 3, 2025 Stockholders entitled to vote at the 2025 Annual Meeting

Proxy statement filing date November 21, 2025 Date definitive proxy statement describing proposals was filed

Key Terms

Annual Meeting of Stockholders, quorum, definitive proxy statement, record date, +1 more

5 terms

Annual Meeting of Stockholders financial

"iSpecimen Inc. convened its 2025 Annual Meeting of Stockholders"

quorum financial

"Because a quorum was not present, the Company adjourned the Annual Meeting"

A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.

definitive proxy statement financial

"proposals set forth in the Company’s definitive proxy statement filed"

A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.

record date financial

"The record date for determination of stockholders entitled to vote"

The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why has iSpecimen (ISPC) not completed its 2025 annual meeting?

iSpecimen has repeatedly adjourned its 2025 Annual Meeting because a quorum was not present on December 31, 2025 and on reconvened dates in January, February, March, and April 2026. Without a quorum, stockholders cannot formally vote on the listed proposals.

When will iSpecimen (ISPC) reconvene its 2025 Annual Meeting of Stockholders?

iSpecimen plans to reconvene its 2025 Annual Meeting of Stockholders on May 8, 2026 at 9:00 a.m. Eastern Time. This new date follows several prior adjournments caused by the failure to achieve a quorum of shares entitled to vote.

What is the record date for voting at iSpecimen’s 2025 annual meeting?

The record date for determining stockholders entitled to vote at iSpecimen’s 2025 Annual Meeting remains November 3, 2025. Only holders of the company’s common stock as of that date are eligible to vote on the meeting’s proposals.

Have iSpecimen’s 2025 annual meeting proposals changed after the adjournments?

No. The company states that no changes have been made to the proposals for the 2025 Annual Meeting. The proposals remain exactly as described in iSpecimen’s definitive proxy statement filed on November 21, 2025 with the Securities and Exchange Commission.

What disclosure did iSpecimen (ISPC) file about its 2025 annual meeting?

iSpecimen filed a Form 8-K under the “Other Events” item explaining that its 2025 Annual Meeting lacked a quorum on multiple dates and was adjourned. The filing also discloses plans to reconvene the meeting on May 8, 2026 using the same proposals.

Which dates did iSpecimen attempt to reconvene its 2025 annual meeting?

iSpecimen reconvened the 2025 Annual Meeting on January 23, 2026, February 13, 2026, March 13, 2026 and April 10, 2026. Each reconvened session was adjourned again because a quorum of stockholders was not present to conduct business.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/13/2026 - 04:05 PM EDT Learn about SEC filing dates

false 0001558569 0001558569 2026-04-10 2026-04-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 10, 2026

iSpecimen Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40501		27-0480143
(State or other jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

8 Cabot Road, Suite 1800

Woburn, MA 01801

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (781) 301-6700

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ISPC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On December 31, 2025, iSpecimen Inc. (the “Company”) convened its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). Because a quorum was not present, the Company adjourned the Annual Meeting to permit additional time for stockholders to vote on the proposals set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 21, 2025 (the “Proxy Statement”).

The Annual Meeting was reconvened on January 23, 2026, February 13, 2026, March 13, 2026 and April 10, 2026. At each reconvened meeting, a quorum was not present and the Annual Meeting was adjourned.

The Company intends to reconvene the Annual Meeting on May 8, 2026 at 9:00 a.m. Eastern Time. The record date for determination of stockholders entitled to vote at the Annual Meeting remains November 3, 2025. No changes have been made to the proposals to be voted on at the Annual Meeting, which are described in the Proxy Statement.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 13, 2026

	iSPECIMEN INC.
	By:	/s/ Katharyn Field
		Name:	Katharyn Field
		Title:	Chief Executive Officer

2

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB